Posted on January 11, 2022 at 8:30 p.m.
Tell Health Canada to Move It
When Pfizer became available the approval process to get it into arms seemed lightning fast even though one massive submission was made in the fall of 2020.
Medicago has completed it studies and last fall submitted it’s final phase 3 results to Health Canada for approval. Medicago in agreement with Health Canada used a rolling submission approach presenting information about it’s progress on an ongoing basis throughout it’s development and testing process.
How long is it going to take to get the first plant based Virus Like Particle (VLP) non-mRNA vaccine to market?
Do our governments not realize that this more natural solution to vaccination could very well get those who have simply been vaccine hesitant to accept this vaccine?
Come on Mr. Prime Minister and Premiers step up to the plate and start promoting this non-genetic solution for the benefit of Canada and the world at large.
About Medicago
“Medicago is on a mission to help improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-based therapeutics. We are proudly rooted in Quebec, with manufacturing capacity in both Canada and the US. Our passionate and curious team of over 500 scientific experts and employees are dedicated to using our technology to provide rapid responses to emerging global health challenges, and to advancing therapeutics against life-threatening diseases worldwide.
Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation.” For more information: www.medicago.com
“We are pleased to submit our Phase 3 data as the final portion of the rolling submission for our COVID-19 vaccine candidate for review,” said Dr. Judith Atkins, Vice-President of Regulatory Affairs at Medicago. “We are grateful to Health Canada for their review, and we hope this brings Canadians and the world one step closer to having greater vaccine diversity.”
Thomas Breuer, Chief Global Health Officer, GSK, added: “We are one step closer to our goal of making this innovative adjuvanted, plant-based vaccine available. As a refrigerator-stable option that builds on our established adjuvant technology, we are hopeful it will play an important role in the efforts to overcome the COVID-19 pandemic.”
About Mitsubishi Tanabe Pharma Corporation
“Mitsubishi Tanabe Pharma Corporation (MTPC) Group, the majority parent company of Medicago, is one of the large Japanese pharmaceutical companies, with its headquarters in Osaka, Japan. It positions vaccines as one of its key R&D areas under its Medium-Term Management Plan 21-25 and is also working to develop new modalities of vaccines. MTPC Group will further contribute to the prevention of infectious diseases which is one of the world’s important social issues, by delivering a new option of plant-based VLP vaccine as a new type of vaccine.” For further information please visit https://www.mt-pharma.co.jp/e/.
Conclusion
It is time our governments stop pushing these mRNA vaccines and start focusing on a non genetic solution developed here at home in Canada. So Get the Lead Out and bring this product to market sooner than later.
My website is https://lisaparentcovid-19.ca